Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters

Database
Language
Affiliation country
Publication year range
1.
Anticancer Res ; 25(6C): 4743-6, 2005.
Article in English | MEDLINE | ID: mdl-16334170

ABSTRACT

BACKGROUND: Syndecan-1 (CD138) is expressed by the Hodgkin-Reed-Sternberg (HRS) cells of classic Hodgkin's lymphoma (cHL), but not in nodular lymphocyte-predominant HL. Syndecan-1 may be involved in the interaction between HRS cells and the cellular and stromal microenvironment typical of nodular sclerosing HL. PATIENTS AND METHODS: Serum levels of soluble syndecan-1 were determined by ELISA in 66 patients with HL and 14 age- and sex-matched healthy individuals. RESULTS: The levels of syndecan-1 were higher in HL patients than controls (100.2 +/- 35.9 ng/ml vs. 67.9 +/- 24.5 ng/ml, p < 0.001). They marginally correlated with advanced age (p = 0.06), male gender (p = 0.07) and consequently high IPS (p = 0.01), but did not correlate with markers of tumor burden and prognosis, including serum interleukin-10 and soluble CD30. At 6 years, failure-free survival was 70 +/- 9% vs. 50 +/- 11% (p = 0.32) for patients with serum soluble syndecan-1 levels above or below the observed median value of 91 ng/ml. CONCLUSION: The serum levels of syndecan-1 were elevated in patients with HL, but were not strongly correlated with other potential prognostic factors. Their effect on prognosis deserves further evaluation.


Subject(s)
Hodgkin Disease/blood , Membrane Glycoproteins/blood , Proteoglycans/blood , Adolescent , Adult , Aged , Disease-Free Survival , Female , Hodgkin Disease/pathology , Humans , Male , Middle Aged , Syndecan-1 , Syndecans
2.
Br J Haematol ; 137(3): 240-3, 2007 May.
Article in English | MEDLINE | ID: mdl-17408464

ABSTRACT

The prognostic value of baseline serum free light chain ratio (sFLCR) was investigated in 94 multiple myeloma (MM) patients. sFLCR was calculated as kappa/lambda or lambda/kappa, depending on the patients' dominating monoclonal light chain. Median baseline sFLCR was 3.57 in kappa-MM patients, 45.09 in lambda-MM. 'High' sFLCR (> or = the observed median value for kappa- and lambda-MM respectively) correlated with elevated serum creatinine and lactate dehydrogenase, extensive marrow infiltration and light chain type MM. The 5-year disease-specific survival was 82% and 30% in patients with sFLCR lower than and equal or greater than the median, respectively (P = 0.0001). sFLCR was an independent prognostic factor.


Subject(s)
Immunoglobulin Light Chains/blood , Multiple Myeloma/diagnosis , Aged , Biomarkers/blood , Bone Marrow/pathology , Creatinine/blood , Female , Humans , Immunoglobulin kappa-Chains/blood , Immunoglobulin lambda-Chains/blood , L-Lactate Dehydrogenase/blood , Male , Middle Aged , Multiple Myeloma/blood , Multiple Myeloma/mortality , Prognosis , Survival Analysis
SELECTION OF CITATIONS
SEARCH DETAIL